Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption, and biologic response

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 4, 2006, Pages 510-521

  Suman, Julie D ^a   Laube, Beth L ^b   Dalby, Richard ^c  

^a Next Breath LLC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Areosol; Bioequivalence; Gamma scintigraphy; In vitro in vivo correlation; Nasal deposition; Nasal spray pump

Indexed keywords

NICOTINE;

ADULT; AEROSOL; AQUEOUS SOLUTION; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; FOOD AND DRUG ADMINISTRATION; GAMMA SCINTIGRAPHY; HEART FUNCTION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; NOSE AIRFLOW; PARAMETER; PARTICLE SIZE; PHARMACODYNAMICS; PRACTICE GUIDELINE; STATISTICAL SIGNIFICANCE;

ABSORPTION; ADMINISTRATION, INTRANASAL; AEROSOLS; HUMANS; MODELS, ANATOMIC; NASOPHARYNX; NEBULIZERS AND VAPORIZERS; NICOTINE; REPRODUCIBILITY OF RESULTS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 33846059406     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.510     Document Type: Article

References (24)

1. Byron, P.R. 2002. In vitro bioequivalence of particle size distributions: a commentary on PDA's draft guidance. Presented at Respiratory Drug Delivery VIII, Tucson, Arizona.
2. FDA. 2003. U.S. FDA Draft Guidance for Industry. Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. FDA, Bethesda, MD.
3. Suman, J.D., B.L. Laube, T. Lin, et al. 2002. Relevance of in vitro tests of nasal solutions to predict in vivo deposition. Pharm. Res. 19:1-6.
4. Harris, A.S., I.M. Nilsson, Z.G. Wagner, et al. 1986. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J. Pharm. Sci. 75:1085-1088.
5. Harlharan, M., T. VanNoord, and J.F. Greden. 1988. A high-performance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clin. Chem. 34:724-729.
6. Suman, J.D., B.L. Laube, and R. Dalby. 1998. Nasal nebulizers versus aqueous nasal spray pumps: a comparison of deposition patterns in human volunteers. In Respiratory Drug Delivery VI, eds: R.N. Dalby, P.R. Byron, J. Peart, and S.J. Farr. Interpharm Press, Buffalo Grove, IL, 211-218.
7. Sutherland, G., M.A. Russell, J. Stapleton, et al. 1992. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 108:512-518.
8. Guthrie, S.K., J.K. Zubieta, L. Ohl, et al. 1999. Arterial/venous plasma nicotine concentrations following nicotine nasal spray. Eur. J. Clin. Pharmacol. 55:639-643.
9. Drug Dex® System. 2006. Thomsom Micromedex.
10. Suman, J.D., B.L. Laube, and R. Dalby. 1999. Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and aqueous spray pump. Pharm. Res. 16:1648-1652.
11. Smith, G., C. Hiller, M. Mazumder, et al. 1980. Am. Rev. Respir. Dis. 121:513-517.
12. Newman, S.P., K.P. Steed, J.G. Hardy, et al. 1994. The distribution of an intranasal formulation in healthy volunteers: effect of different administration techniques. J. Pharm. Pharmacol. 46:657-660.
13. Newman, S.P., G.R. Pitcairn, and R.N. Dalby. 2004. Drug delivery to the nasal cavity: in vitro and in vivo assessment. Crit. Rev. Drug Carrier Systems 21:21-66.
14. Nicotrol NS (nicotine nasal spray) package insert. 1996. McNeil Consumer Products Co., Division of McNeil-PPC, Inc., Fort Washington, PA.
15. Kublick, A., and M.T. Vidgren. 1998. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug. Del. Rev. 29:157-177.
16. Mygind, N. 1993. Upper airway: structure, function and therapy. In F. Moren, M.B. Dolovich, M.T. Newhouse, et al, eds. Aerosols in Medicine: Principles, Diagnosis and Therapy. Elsevier Publishers B.V., Amsterdam, The Netherlands, 1-26.
17. Newman, S.P., F. Moren, and S.W. Clarke. 1987. The nasal distribution of metered dose inhalers. J. Laryngol. Otol. 101:127.
18. Nsouli, T.M., J.B. Williams, K.K. Johnson, et al. 2003. Epistaxis and nasal steroid usage in allergic rhinitis: can we prevent it? Presented at the American College of Allergy, Asthma, and Immunology Annual Meeting, New Orleans.
19. Benniger, M.S., et al. 2004. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg. 130:5-24.
20. Pomerleau, O.F., M. Hariharan, C. S. Pomerleau, et al. 1993. Difference between smokers and never-smokers in sensitivity to nicotine: a preliminary report. Addiction 88:113-118.
21. Johansson, C.J., P. Olsson, M. Bende, et al. 1991. Absolute bioavailability of nicotine applied to different nasal regions. Eur. J. Clin. Pharmacol. 41:585-588.
22. Prasad, A.K. 2005. Understanding dynamic airflow within the nasal passage. Presented at Nasal Drug Delivery: BBB, Regulation, Formulation and Delivery Systems Advances, Washington, D.C.
23. Kimbell, J.S., J.D. Schroeter, B. Asgharian, et al. 2004. Optimization of nasal delivery devices using computational models. In Respiratory Drug Delivery IX. Vol. 1. eds: R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, and S.J. Farr. Interpharm Press, Buffalo Grove, IL, 233-238.
24. Guo, Y., B.L. Laube, and R. Dalby. 2005. The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm. Res. 22:1871-1878.